FHX

3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxidanylidene-propanenitrile

Created:2020-05-14
Last modified:  2020-06-24

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count41
Chiral Atom Count2
Bond Count44
Aromatic Bond Count10
2D diagram of FHX
Toggle HydrogenToggle Labels

Chemical Component Summary

Name3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxidanylidene-propanenitrile
Systematic Name (OpenEye OEToolkits)3-[(3~{S},4~{R})-3-methyl-7-(7~{H}-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxidanylidene-propanenitrile
FormulaC16 H18 N6 O
Molecular Weight310.354
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385C[CH]1CN(C(=O)CC#N)[C]12CCN(C2)c3ncnc4[nH]ccc34
SMILESOpenEye OEToolkits2.0.7CC1CN(C12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N
Canonical SMILESCACTVS3.385 C[C@H]1CN(C(=O)CC#N)[C@]12CCN(C2)c3ncnc4[nH]ccc34
Canonical SMILESOpenEye OEToolkits2.0.7 C[C@H]1CN([C@]12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N
InChIInChI1.03 InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
InChIKeyInChI1.03 LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB16133 
NameDelgocitinib
Groups investigational
DescriptionDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.[L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703]
Synonyms
  • Delgocitinib
  • 1,6-DIAZASPIRO(3.4)OCTANE-1-PROPANENITRILE, 3-METHYL-.BETA.-OXO-6-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (3S,4R)-
  • 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
IndicationDelgocitinib is indicated for the treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.[L51589]
Categories
  • Agents for Dermatitis, Excluding Corticosteroids
  • Dermatologicals
  • OAT3/SLC22A8 Substrates
  • OCT2 Substrates
  • P-glycoprotein substrates
ATC-CodeD11AH11
CAS number1263774-59-9

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Tyrosine-protein kinase JAK1MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRL...unknowninhibitor
Tyrosine-protein kinase JAK2MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKS...unknowninhibitor
Tyrosine-protein kinase JAK3MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLA...unknowninhibitor
Non-receptor tyrosine-protein kinase TYK2MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESS...unknowninhibitor
ATP-dependent translocase ABCB1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL4297507
PubChem 50914062
ChEMBL CHEMBL4297507